Par Pharmaceutical, Inc. v. Merck Sharp & Dohme Corp.

I'll research this case thoroughly before drafting the overview.

I have strong material. Let me fill a few gaps on the related litigation, the settlement, IPRs, and market context.

Case Overview and Background

The parties. This is a classic Hatch-Waxman innovator-versus-generic dispute, not an NPE/PAE assertion. Plaintiff Par Pharmaceutical, Inc. (Chestnut Ridge, NY) is a generic-drug manufacturer and, per its corporate disclosure statement, a wholly-owned indirect subsidiary of Endo International plc (D.I. 2). Its affiliate Anchen Pharmaceuticals, Inc. (Irvine, CA) is also a wholly-owned indirect Par/Endo subsidiary and holds the ANDA at issue in the parallel Delaware action. Defendant Merck Sharp & Dohme Corp. is the innovator/brand company — a New Jersey corporation with offices at One Merck Drive, Whitehouse Station/Kenilworth, NJ — that owns and is the assignee of U.S. Patent No. 7,326,708 and holds New Drug Application (NDA) No. 202270 for JANUMET XR (sitagliptin phosphate/metformin HCl extended-release tablets). Merck, not a shell plaintiff, is the patent owner and NDA holder; its only role here is as the branded manufacturer defending the later-expiring salt patent that blocks generic entry (Complaint, ¶¶ 6–7; D. Del. 1:19-cv-00311 Compl.).

The accused product and patent. The accused product is Par's proposed generic version of JANUMET XR — sitagliptin phosphate and metformin hydrochloride extended-release tablets in 50/500 mg, 50/1000 mg and 100/1000 mg strengths — which Par sought to market under an ANDA referencing Merck's NDA No. 202270, with a Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). The single patent asserted in this NJ action is U.S. Patent No. 7,326,708 ("Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor"), issued Feb. 5, 2008, from an application filed June 2004 claiming a June 2003 priority date, and listed in the Orange Book for Janumet XR with a Nov. 24, 2026 expiry extended to May 24, 2027 by pediatric exclusivity. In one line: the '708 patent claims the dihydrogenphosphate (DHP) salt of sitagliptin — specifically the 1:1 salt, its (R)- and (S)-enantiomers, the crystalline monohydrate, and processes for making it — i.e., the salt/polymorph form of the active ingredient, not the sitagliptin compound itself (Google Patents; Merck press release, Sept. 22, 2022). A companion patent, U.S. Pat. No. 8,414,921 (sitagliptin/metformin co-formulation), was litigated in the same family of cases but is not at issue in this NJ docket.

Posture, venue, and why it matters. Par filed this declaratory-judgment action in the District of New Jersey on Feb. 1, 2019, assigned to Judge Madeline Cox Arleo with Magistrate Judge Michael A. Hammer (D.I. 1; docket via UniCourt/Patexia). Par invoked the Hatch-Waxman DJ mechanism (35 U.S.C. § 271(e)(5); 21 U.S.C. § 355(j)(5)(C)(i)(I)) to obtain "patent certainty" after Merck declined to sue within the 45-day window following Par's Oct. 22, 2012 Paragraph IV notice. Venue in New Jersey was grounded on Merck's principal place of business and its own prior ANDA suits filed there (Compl. ¶¶ 10–12). The case proved short-lived: Merck had already sued Par and Anchen in the District of Delaware on Feb. 13, 2019 (No. 1:19-cv-00311-RGA), which was swept into In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902-RGA before Judge Richard G. Andrews. Par voluntarily dismissed the NJ action without prejudice on Feb. 19–20, 2019 (D.I. 5, 6), opting to litigate in Delaware — essentially the entire life of this docket. The broader dispute is notable for several reasons: (1) it illustrates the § 271(e)(5) "reverse" DJ route a generic can use when a brand sits out the 45-day window; (2) the '708 patent anchored a nationwide patent thicket — fourteen-plus generic defendants, an MDL, and a cluster of IPRs (Mylan IPR2020-00040, with Teva, Dr. Reddy's and Sun filing substantially identical petitions and requesting joinder), where the PTAB upheld the challenged claims in May 2021 and the Federal Circuit affirmed on substantial-evidence grounds on Sept. 29, 2022 (Mylan Pharms. v. Merck, No. 2021-2122), while Judge Irene Keeley in the N.D. W. Va. bench trial found the '708 and '921 patents valid and infringed (opinion filed Oct. 26, 2022); and (3) commercially, the case sits inside Merck's settlement wave allowing generic sitagliptin entry in May 2026 (Januvia/Janumet) and July 2026 (Janumet XR) — ahead of the patent's own 2026/2027 expiry — with Par/Anchen's Delaware action ending in a consent judgment on March 2, 2021 (D. Del. D.I. 154). The payoff for Par came on July 24, 2026, when Par Health launched the first and only FDA-approved generic JANUMET XR in the U.S., in a market segment worth roughly $269.9 million in annual sales (IQVIA, 12 months ended May 2026) (Par Health/PRNewswire; Optum first-time-generic bulletin).

Sourcing caveats. The specific terms of any Par–Merck settlement/first-to-file exclusivity arrangement are not public and are not reflected in this NJ docket; the NJ disposition of record is a voluntary dismissal without prejudice (D.I. 6, signed by Judge Arleo), while the substantive resolution is the March 2021 Delaware consent judgment. Merck's public statements (investor 10-Qs and press releases) support the May 2026/July 2026 entry dates and the IPR/Federal Circuit outcome, but I did not find a publicly filed opinion resolving the Par/Anchen merits — that dispute settled before trial.

I'll research this case thoroughly using web searches.

Let me gather details on the IPR proceedings and confirm the docket specifics.

Let me get more specifics on the Par docket and the strategic context of the quick dismissal.

Key Legal Developments & Outcome — Par Pharmaceutical, Inc. v. Merck Sharp & Dohme Corp., No. 2:19-cv-04432 (D.N.J.)

Bottom line up front: This particular D.N.J. docket was a short-lived declaratory-judgment (DJ) action that lived only ~19 days. Par filed it to force "patent certainty" on U.S. Patent No. 7,326,708 (the sitagliptin dihydrogenphosphate "salt" patent) after Merck declined to sue; Merck's riposte was to file its own infringement actions in Delaware (later consolidated in an MDL), and Par then voluntarily dismissed the New Jersey case without prejudice. All substantive merits fight over the '708 patent — the real war over this patent — occurred in the Delaware sitagliptin MDL, the N.D. W. Va. bench trial (Merck v. Mylan), and a parallel Mylan IPR that reached the Federal Circuit. The metadata "settled" designation reflects that Par's underlying ANDA dispute was ultimately resolved by a consent judgment/settlement in the Delaware MDL, not by anything on this D.N.J. docket.

---

1. Filing & Initial Pleadings

• 2012-10-22 — Pre-litigation Paragraph IV notice. Par sent Merck a Paragraph IV certification notice for its ANDA product (generic JANUMET XR, referencing NDA No. 202270). Merck did not file an infringement suit within the statutory 45-day window, which under 35 U.S.C. § 271(e)(5) and § 355(j)(5)(C) gave Par a right to seek a DJ of invalidity. (Compl. ¶¶5, 17–18.)
• 2019-02-01 — Complaint filed. Par Pharmaceutical, Inc. (a New York corporation; corporate parent Endo International PLC) filed a one-count declaratory judgment complaint seeking a declaration that the claims of the '708 patent are invalid. Dkt. 1. Counsel of record was Jason B. Lattimore (The Law Office of Jason B. Lattimore, Esq. LLC). Dkt. 2 (Corporate Disclosure Statement).
• Assignment. Case assigned to Judge Madeline Cox Arleo and Magistrate Judge Michael A. Hammer (D.N.J.).
• 2019-02-07 — Summons issued (Dkt. 4); AO120 Patent/Trademark Form filed (Dkt. 3).
• No answer and no counterclaims. The case was dismissed before Merck answered or appeared. There is no Rule 12 motion, no answer, no counterclaim on this docket.

Strategic context: This was a textbook "DJ-forcing" maneuver. Per Merck's SEC disclosures, when Par filed in New Jersey, Merck responded by filing its own patent infringement lawsuits in the District of Delaware against Par and other companies signaling intent to market generic sitagliptin products before the later-expiring salt/polymorph and Janumet-formulation patents expired. Par then abandoned the New Jersey venue. (Merck & Co. Form 10-Q, Q1 2019 and Q3 2020.)

2. Pre-Trial Motions of Substance

None. The D.N.J. case never reached any dispositive, stay, or transfer motion. There was no motion to dismiss, no motion to transfer, no motion to stay pending IPR, and no summary-judgment practice on this docket. (See Unicourt/Patexia docket summaries: only Dkts. 1–6 exist.)

3. Claim Construction (Markman)

Not reached. The case was dismissed before any scheduling order, joint claim-construction statement, or Markman hearing. Notably, the "1:1 stoichiometry" and hydrate limitations of claim 1 — the terms that later drove the merits — were never construed on this docket.

4. Discovery Milestones

None of strategic significance. No scheduling order issued and no discovery was taken in D.N.J.

5. Trial Events, Verdict, Post-Trial Motions

None. No trial, verdict, JMOL, new-trial, or fee motion on this docket.

6. Settlement / Dismissal / Final Disposition (Local Docket)

• 2019-02-19 — Notice of Voluntary Dismissal Without Prejudice filed by Par. Dkt. 5.
• 2019-02-20 — Order of Voluntary Dismissal Without Prejudice signed by Judge Arleo (entered 2019-02-22, Dkt. 6), each party bearing its own fees and costs.
• Case status: Disposed (voluntarily dismissed). This is the final disposition of No. 2:19-cv-04432.

Where the dispute actually resolved (Delaware MDL):

• Par's and Anchen's '708 dispute was litigated within In re Sitagliptin Patent Litigation, MDL No. 19-2902-RGA (D. Del.), and specifically Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc., C.A. No. 19-311-RGA (D. Del.) (naming Anchen and Par).
• 2021-03-02 — Consent Judgment signed by Judge Richard G. Andrews, Dkt. 154 in C.A. 19-311. It recites a negotiated Settlement Agreement, defines the "Licensed Patent" as U.S. Patent No. 7,326,708, defines the "Anchen Product" (ANDA No. 204144), enjoins Anchen/Par from infringing the '708 patent except as authorized by the Settlement Agreement, dismissed all claims/counterclaims with prejudice without costs or fees, and retains jurisdiction to enforce. This is the instrument by which Par's '708 exposure was formally settled.
• Merck publicly stated it settled with ~22 generic companies allowing generic entry May 2026 (JANUVIA/JANUMET) and July 2026 (JANUMET XR) "or earlier under certain circumstances."

7. Parallel PTAB (IPR) Proceedings on the '708 Patent & Their Effect

• 2019-10-30 — IPR2020-00040 filed by Mylan Pharmaceuticals Inc. against claims 1–4, 17, 19, and 21–23 of the '708 patent (anticipation by Merck's own WO 2003/004498 / U.S. 6,699,871 "Edmondson," and obviousness over Edmondson + Brittain + Bastin).
• 2020-05-12 — Institution (Board found a reasonable likelihood of unpatentability).
• 2021-05-07 — Final Written Decision in Merck's favor: all challenged claims not shown to be unpatentable (2021 WL 1833325). Key holdings: no express or inherent anticipation of the 1:1 sitagliptin DHP salt; Merck could antedate Edmondson for claims 1, 2, 17, 19, 21–23 (Merck's earlier reduction to practice) and pre-AIA § 103(c) common-ownership barred the '871 reference; claims 3 and 4 (S- and R-configurations/monohydrate) not obvious (no motivation, no reasonable expectation of success).
• 2022-09-29 — Federal Circuit affirmed in a precedential opinion, Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp., 50 F.4th 147 (Fed. Cir. 2022) (No. 2021-2121; Lourie, J., joined by Reyna and Stoll, JJ.). The court applied the In re Petering "at once envisage" standard and found a class of ~957 predicted salts over 33 compounds and 8 preferred acids insufficient; substantial evidence supported the non-anticipation and non-obviousness findings.
• 2023-02-03 — Rehearing denied (combined panel and en banc petition denied per curiam; PTAB docket shows a final entry ~2023-09-06, consistent with mandate/termination).

Effect on this litigation: The IPR was not filed by Par and was not parallel to a live D.N.J. case — the New Jersey action was already dismissed by the time Mylan petitioned (Oct 2019). It nevertheless became the principal validity battleground for the '708 patent, and the Merck-favorable FWD + Federal Circuit affirmance foreclosed the invalidity theory that Par (and other generics) had relied on, materially strengthening Merck's settlement leverage across the sitagliptin generics docket — which likely contributed to the Par/Anchen consent judgment and the wave of ~22 settlements.

Closely related parallel merits case (context): Merck Sharp & Dohme LLC v. Mylan Pharmaceuticals Inc., No. 1:19-cv-00101 (N.D. W. Va., Judge Keeley) — five-day bench trial December 2021, decision 2022-09-21/26 upholding validity and infringement of '708 claim 3 and '921 claim 1 (rejecting OTDP and § 112 challenges). Mylan/Viatris appealed; the parties later settled, with Viatris agreeing to voluntarily dismiss its Federal Circuit appeal following entry of an amended final judgment.

---

Present Posture

• No. 2:19-cv-04432 (D.N.J.): Closed — voluntary dismissal without prejudice, each side bearing its own fees/costs (Dkt. 6, 2019-02-20). Consistent with the "settled" case metadata, the operative resolution for Par occurred via the Delaware MDL consent judgment (2021-03-02).
• '708 patent status: upheld as valid across the PTAB (FWD 2021-05-07), the Federal Circuit (2022-09-29), and the N.D. W. Va. bench trial (2022-09-21). Orange Book expiry 2026-11-24, extended by pediatric exclusivity to 2027-05-24. Merck's generic settlements permit entry ~May/July 2026.

Sourcing caveats: Docket specifics for this case (filings, Dkts. 1–6, judges, counsel, dates) are well corroborated by docket aggregators (Unicourt/Patexia) and by the complaint text and Merck's SEC 10-Qs. The pleadings in No. 2:19-cv-04432 were never developed (no answer, no motions), so any account of merits "rulings" in this case would be fabricated — those rulings belong to the Mylan IPR/Federal Circuit and N.D. W. Va. tracks. I did not independently verify whether additional IPR petitioners (e.g., Sun) filed separate IPRs on the '708 patent; only IPR2020-00040 (Mylan) is confirmed by the Federal Circuit opinion.

I'll research the docket and counsel for the plaintiff in this case.

Let me pull the complaint itself (signature block) and research the counsel's firm.

Let me verify the complaint's signature block and check the RECAP docket for any additional appearances.

Plaintiff's counsel of record — Par Pharmaceutical, Inc. v. Merck Sharp & Dohme Corp., No. 2:19-cv-04432 (D.N.J.)

Bottom line: Only one attorney appeared for the plaintiff in this case. Because the action was filed on February 1, 2019 and voluntarily dismissed roughly three weeks later (before any defendant answer or motion), the record is very thin — there is no of-counsel or pro hac vice roster to report.

Counsel for Plaintiff Par Pharmaceutical, Inc.

Sourcing and how it was verified

• Docket entries (via UniCourt/Patexia mirrors of the D.N.J. docket and paragraphfour.com's copy of the complaint): the complaint (D.E. 1, filed 2/1/2019), the Corporate Disclosure Statement (D.E. 2), and the Notice of Voluntary Dismissal (D.E. 5, filed 2/19/2019, "by PAR PHARMACEUTICAL, INC. (LATTIMORE, JASON)") all carry only Lattimore's name. The signature block of the complaint reads "s/ Jason B. Lattimore … Counsel for Par Pharmaceutical, Inc., 55 Madison Avenue, Suite 400, Morristown, NJ 07960."
• Order of dismissal: D.E. 6 — "ORDER OF VOLUNTARY DISMISSAL WITHOUT PREJUDICE with each party bearing its own fees and costs," signed by Judge Madeline Cox Arleo on 2/20/2019 (entered 2/22/2019).
• Attorney profile corroboration: Super Lawyers, Cornell Law's lawyer directory, and CourtListener party records (e.g., Valeant v. Actavis, No. 2:17-cv-12857 (D.N.J.), where he is listed as LEAD ATTORNEY) confirm firm name, Morristown office, and contact details.

Explicit caveats

• No of-counsel or additional plaintiff attorneys appear on this docket. I could not retrieve the OCR'd full text of the complaint's final page to rule out an "Of Counsel" block listing a non-appearing firm. By contrast, in Par/Endo's later matters (e.g., Endo Par Innovation Co. v. Deva Holding, 2023), Axinn, Veltrop & Harkrider LLP appeared as of counsel alongside Lattimore — but no such firm is listed in this 2019 case, and Axinn does not appear on this docket.
• No in-house counsel of record is identified for Par; the Corporate Disclosure Statement identifies Endo International plc as Par's corporate parent (Par was an Endo subsidiary), but no Endo in-house attorney entered an appearance.
• Defendant's counsel: none appears — Merck never answered, moved, or entered an appearance before dismissal. If you need Merck's anticipated counsel, that would require inference, which I won't do here.
• Status discrepancy: your case metadata says "settled," while the docket reflects a voluntary dismissal without prejudice under Rule 41(a)(1)(A) (D.E. 5–6). Dismissal with each side bearing its own costs is consistent with a negotiated resolution, but the docket itself does not use the word "settled."
• Primary-source access limitation: I was working from third-party mirrors of the docket (UniCourt, Patexia, paragraphfour.com, CourtListener), not a live PACER docket pull. If you need a certified attorney list, the D.N.J. docket sheet for 2:19-cv-04432 (attorney/party tab) is the controlling source.

I'll research the docket and counsel appearances for this short-lived NJ action.

Now let me check the CourtListener/RECAP docket for any defendant appearances, and identify Merck's counsel in the related Delaware/MDL actions.

Let me verify the full docket text and check for any defendant appearance, plus Merck's counsel in the related Delaware Anchen case.

Counsel of Record for the Defendant (Merck Sharp & Dohme Corp.) — D.N.J. No. 2:19-cv-04432

Bottom line: there is no defendant-side counsel of record in this docket

This is the single most important finding, and it is a direct consequence of how short-lived this case was. No attorney ever entered an appearance for Merck Sharp & Dohme Corp. in the New Jersey action. The docket for 2:19-cv-04432 contains only six substantive entries over its 19-day life:

(Patexia docket, 2:19-cv-04432; UniCourt docket, 2:19-cv-04432)

There is no answer, no Rule 12 motion, no motion for pro hac vice admission, no corporate disclosure statement from Merck, and — notably — no return of service on the docket. The summons issued Feb. 7, 2019 and Par filed its voluntary dismissal just twelve days later. The UniCourt and Patexia attorney/firm listings for this case name only one attorney: Jason B. Lattimore, for the plaintiff Par Pharmaceutical, Inc. (UniCourt, "Attorney/Law Firm Details — Plaintiff Attorney: JASON B. LATTIMORE").

Why there was no appearance. This is a venue-race story rather than a merits story: Merck sued Par and Anchen in the District of Delaware on Feb. 13, 2019 (Merck Sharp & Dohme Corp. v. Anchen Pharms., Inc., No. 1:19-cv-00311-RGA, D. Del.), which gave Par the forum it apparently preferred and mooted the New Jersey DJ vehicle. Par dismissed here six days later. The eleven-day window between summons issuance and dismissal, layered on top of the MDL/tag-along activity, left essentially no occasion for a Merck appearance in New Jersey.

Caveat on sourcing: the parties' 2019 docket-entry data above is drawn from public aggregators (Patexia, UniCourt) rather than a first-hand PACER docket-sheet pull, and PACER's separate internal attorney/participant list can in rare instances reflect appearances not captured in the entry text. I could not independently confirm the attorney list through PACER, so I state the "no appearance" conclusion with that qualification — but every public source I located for this docket shows the same six entries and plaintiff-side counsel only, and the case closed before any answer deadline could have run (Par's own DJ complaint was filed only after Merck had blown the 45-day window, and Merck's answer would not have come due until ~mid-March 2019 in any event).

---

The counsel who did represent Merck on the '708 patent against Par/Anchen (related case)

Because the defendant never appeared in New Jersey, the only defensible way to answer "who represented Merck against Par" is to look to the parallel Delaware action on the same ANDA and the same patent — No. 1:19-cv-00311-RGA, Merck Sharp & Dohme Corp. v. Anchen Pharmaceuticals, Inc. and Par Pharmaceutical, Inc., later consolidated into In re Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902-RGA. Merck's appearance there was a two-firm structure: Williams & Connolly LLP (Washington, D.C.) as lead merits/I.P. counsel and McCarter & English, LLP (Wilmington, Delaware) as Delaware counsel.

Lead trial / merits counsel — Williams & Connolly LLP, 725 Twelfth Street, N.W., Washington, D.C. 20005

• Bruce R. Genderson — lead Williams & Connolly partner on the sitagliptin matters; veteran Hatch-Waxman and Federal Circuit advocate (longtime counsel in Merck's and other life-sciences patent appeals).
• Jessamyn S. Berniker — partner; designated first back-up IPR counsel for Merck on the '708 patent.
• Stanley E. Fisher (Reg. No. 55,820) — designated lead counsel in Merck's IPR2020-00040 patent-owner filings.
• Alexander S. Zolan — pro hac vice; Merck's counsel in the MDL and in the IPRs.
• Elise M. Baumgarten — pro hac vice; MDL and IPR counsel.
• Shaun P. Mahaffy (Reg. No. 75,534) and Anthony H. Sheh (Reg. No. 70,576) — associates; Sheh was designated backup IPR counsel and declared that he was "actively engaged in the representation of Patent Owner Merck Sharp & Dohme Corp. … in related matters in federal district courts, including the assertion of U.S. Patent No. 7,326,708."
• Other listed W&C attorneys across the MDL/IPR filings: Jingyuan Luo, Sarahi Uribe, Jihad J. Komis, Jeffrey G. Ho.

Delaware / local counsel — McCarter & English, LLP, Renaissance Centre, 405 N. King Street, 8th Floor, Wilmington, DE 19801

• Michael P. Kelly — firm partner; docket-listed LEAD ATTORNEY for Merck in MDL 19-2902.
• Daniel M. Silver and Alexandra M. Joyce — Delaware counsel of record for Merck; both appear on the Anchen/Par complaint and on the March 1, 2021 consent-judgment papers.

(Anchen/Par complaint signature block, D. Del. 1:19-cv-00311, D.I. 1; D. Del. D.I. 154 (consent judgment, Mar. 1, 2021); MDL 19-2902 docket sheet reflecting the full Merck roster; D. Del. 1:19-cv-00311 docket; IPR2020-00040 Ex. 2014 (Sheh Declaration))

One firm to exclude from the Par/Anchen representation: Katten Muchin Rosenman LLP (Deepro R. Mukerjee, Lance A. Soderstrom, New York) also appeared as Merck's counsel on the '708 patent — but in the N.D. W. Va. Mylan action (1:19-cv-00101-IMK), a different defendant group, not against Par/Anchen. Likewise, the N.D. W. Va. joint status report signature blocks pair W&C with Katten, not McCarter (N.D. W. Va. 1:19-cv-00101, D.I. 54).

In-house counsel: I found no publicly identified Merck in-house attorney associated with either the New Jersey DJ action or the Par/Anchen Delaware action. Merck's IP litigation has been run through outside counsel in these matters; I will not speculate as to an in-house name.

---

For completeness: plaintiff's counsel of record in 2:19-cv-04432

• Jason B. Lattimore — local counsel of record and sole attorney for Par on the NJ docket; The Law Office of Jason B. Lattimore, Esq., LLC, 55 Madison Avenue, Suite 400, Morristown, NJ 07960. (New Jersey solo/ADR-side practitioner; his name appears as the CM/ECF filer on every entry in this docket.)
• Of counsel (New York/Washington) — Axinn, Veltrop & Harkrider LLP, listed on the complaint as "pro hac vice to be submitted" but never actually admitted because the case was dismissed: David H. Silverstein (114 W. 47th St., 22nd Fl., New York, NY), Aziz Burgy and Christopher M. Gallo (950 F St., N.W., 7th Fl., Washington, D.C.). All three did appear pro hac vice for Par/Anchen in the Delaware action and were admitted there on March 12–13, 2019 (NJ complaint signature block; D. Del. 1:19-cv-00311 docket, Mar. 7 & Mar. 13, 2019 entries).

---

Cross-reference flag

The previously generated case-overview section characterizes the NJ disposition correctly (D.I. 5–6, voluntary dismissal without prejudice) and cites the same docket. This counsel analysis is consistent with it and adds one nuance worth flagging for the case file: the overview's reference to Par's "NJ action" counsel should be understood as plaintiff-side only. Because Merck never appeared in New Jersey, any statement that Merck was "represented by" McCarter & English / Williams & Connolly in this case would be inaccurate — that attribution belongs to the Delaware action (1:19-cv-00311-RGA) and MDL 19-2902, not to 2:19-cv-04432.

Unverified items I am explicitly not asserting: (1) that no Merck appearance of any kind exists in the court's internal attorney record (public aggregators show none, but I did not pull the CM/ECF attorney list directly); and (2) any in-house Merck counsel name for this matter.